PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) invites investors, the media and the general public to listen to a live webcast of its 2008 R&D Day event. The webcast will begin on Thursday, July 10, 2008 at 8:00 a.m. Eastern Time and is expected to last approximately four hours. Members of Medarex's senior management will provide an overview of the company's strategy, progress and new information about advancements in the research and development pipeline and other ongoing programs.
Interested parties may access the live webcast through the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the event will be available for at least 14 days following the event.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody product
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved